Vale S.A. (VALE)

Vale's stock is trading near the bottom of its 52-week range and has fallen well below its 50-day and 200-day moving averages ($13.37 and $15.12), while analysts remain mostly on the sidelines. The price sits at $11.58, just above its 52-week low of $10.96, and the trailing P/E of 68.12 is far above the sector median of 30.2. Recent rating actions have been steady rather than decisive: Wells Fargo, UBS and Barclays all kept neutral-style ratings in early November, and Freedom Broker kept its Buy. The question for holders is whether the business can rebuild earnings from a thin current profit base.

The stock is down 32.00% over six months and 19.13% over three months, and it sits 23.43% below its 200-day average. The 50-day average is below the 200-day average by 11.61%, a configuration that technical traders usually read as a longer downtrend. Momentum confirms the weakness: the 14-day RSI is 38.5, which is in the bearish zone but not oversold, and the MACD line is negative. The stock did bounce 5.46% over the past week, but that move has not yet pulled the price back above the 20-day EMA.

The trailing P/E of 68.12 is a premium to the sector median of 30.2, but that figure rests on a reported profit that is very thin. Reported earnings per share over the last 12 months were $0.17, and the net profit margin is 1.01%, while the operating margin is 19.31%. The gap between operating and net margins is wide, and return on equity is only 0.26% against a sector median of 17.9%. On sales the stock looks cheaper than peers, with a price-to-sales ratio of 1.26 against a sector median of 4.2.

Of 25 analysts with a current rating, 12 rate the stock buy or strong buy, 12 rate it hold, and one rates it sell or strong sell. Twelve months ago the buy count was 10 of 25, so the split has moved toward buy slightly. Wells Fargo kept its Equal-Weight rating on November 3, 2026, UBS kept its Neutral rating on November 2 and again on October 21, Barclays kept its Equal-Weight rating on November 2, and Freedom Broker kept its Buy rating on November 2. Scotiabank was the one upgrade, moving to Sector Outperform from Sector Perform on October 19, 2026. The median 12-month analyst target is $15.00, which sits 29.5% above the price of $11.58. The analysts' average EPS estimate for next fiscal year (2027) is $1.81, which is expected to grow 9.2% from this year's estimate.

The trailing dividend yield is 6.91%, based on an annual dividend of $0.80 per share. Because the dividend is large relative to the reported $0.17 of earnings per share over the last year, its sustainability depends on cash flow and on the earnings rebuilding that analysts forecast. Debt-to-equity is 0.55, which gives the balance sheet a moderate footing.

The base case is that the stock keeps trading in a weak, range-bound pattern near its 52-week low until earnings stop shrinking. Analysts expect EPS to fall 9.1% this fiscal year to $1.66 and then rise 9.2% to $1.81 in 2027, and revenue is expected to grow 6.8% this year, so the recovery depends on that second-half and next-year growth actually arriving. Conditions that would improve the picture are a price that reclaims the 20-day EMA and 50-day SMA, and revenue growth that turns positive after the 3.90% decline in the latest quarter. Conditions that would worsen it are a break below the $10.96 low, further weakness in the iron ore and base-metals prices the business depends on, or a shift in analyst ratings toward sell. The median analyst target of $15.00 sits well above the price, but the target range runs from $9.50 to $22.00, so the spread of views is wide. These are scenarios, not forecasts.

Support sits at the 52-week low of $10.96, the nearest level below the price and the point where the stock would be testing its lowest trading of the past year. Above the price, the nearest resistance is the 20-day EMA at $12.04, which a rebound would meet first. The 50-day SMA at $13.37 is the next hurdle and marks where the stock has recently been trading. The 200-day SMA at $15.12 is the longer-term trend line, and the 52-week high of $17.94 is the top of the range.